Tenderwize
Wróć do wyszukiwania

Open-House-Biologika-Rabattverträge 2026-03a - Eculizumab (exkl. der Indikation gMG und NMOSD)

Techniker Krankenkasse·Hamburg, Germany·Deadline Aug 30, 2027 · 370 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-03a - Eculizumab (exkl. der Indikation gMG und NMOSD)

50/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

20 / 100

Czynniki ryzyka

The notice explicitly states this is not a public procurement subject to competition law; legal recourse is via social...

Structured data indicates EU-funded (isEuFunded: true), but XML notice explicitly says no-eu-funds. This may affect rep...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Supply of Eculizumab (excluding indications gMG and NMOSD) under discount agreements with participating health insurance funds.
  • Agreement is open to all eligible pharmaceutical entrepreneurs; no exclusivity granted.
Pokaż pełne podsumowanie

The tender is an Open House procedure for the conclusion of discount agreements (Rabattverträge) under § 130a Abs. 8 SGB V for the active substance Eculizumab (excluding the indications gMG and NMOSD). It is not a public procurement subject to competition law but a voluntary framework. All eligible pharmaceutical entrepreneurs can join at any time during the contract term (max 17 months from 1 April 2026 to 31 August 2027). No estimated value is provided. The procedure is open, with no negotiation on terms. Submission is via email or post, not through the e-procurement portal. The notice is in German, performance in Germany.

Ryzyka

The notice explicitly states this is not a public procurement subject to competition law; legal recourse is via social...

Structured data indicates EU-funded (isEuFunded: true), but XML notice explicitly says no-eu-funds. This may affect rep...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG for the offered medicinal products.
  • Must hold a valid marketing authorization for the medicinal product(s) or be otherwise entitled to place them on the market.

Administrative

  • Must submit a self-declaration regarding authorization and reliability (Anlage 4).

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2026-03a - Eculizumab (exkl. der Indikation gMG und NMOSD)

Conclusion of discount agreements for Eculizumab (excluding gMG and NMOSD) under an Open House procedure. All eligible pharmaceutical entrepreneurs can join at any time during the contract term.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Mar 2026 - Aug 2027

Kategoria

Pharmaceutical products

Termin

Deadline Aug 30, 2027

Szczegóły zamówienia

Data publikacji
24 Feb 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
132076-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3